JP2007511529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007511529A5 JP2007511529A5 JP2006539927A JP2006539927A JP2007511529A5 JP 2007511529 A5 JP2007511529 A5 JP 2007511529A5 JP 2006539927 A JP2006539927 A JP 2006539927A JP 2006539927 A JP2006539927 A JP 2006539927A JP 2007511529 A5 JP2007511529 A5 JP 2007511529A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- dosage form
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 239000006186 oral dosage form Substances 0.000 claims 4
- 239000000843 powder Substances 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 210000005178 buccal mucosa Anatomy 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000008188 pellet Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 206010043778 thyroiditis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52014803P | 2003-11-14 | 2003-11-14 | |
| US60/520,148 | 2003-11-14 | ||
| US56774104P | 2004-05-03 | 2004-05-03 | |
| US60/567,741 | 2004-05-03 | ||
| PCT/US2004/037910 WO2005048935A2 (en) | 2003-11-14 | 2004-11-12 | Methods of modulating immunity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007511529A JP2007511529A (ja) | 2007-05-10 |
| JP2007511529A5 true JP2007511529A5 (cg-RX-API-DMAC7.html) | 2007-12-27 |
| JP5027512B2 JP5027512B2 (ja) | 2012-09-19 |
Family
ID=34623123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006539927A Expired - Fee Related JP5027512B2 (ja) | 2003-11-14 | 2004-11-12 | 免疫調節法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7883703B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2397189B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5027512B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004291107B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2545806C (cg-RX-API-DMAC7.html) |
| DK (1) | DK1687066T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2393674T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL1687066T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005048935A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030108548A1 (en) * | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US7883703B2 (en) | 2003-11-14 | 2011-02-08 | The Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| US8663634B2 (en) * | 2005-07-11 | 2014-03-04 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| US20090258001A1 (en) * | 2006-06-06 | 2009-10-15 | Paul Ponath | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases |
| JP2009544761A (ja) * | 2006-06-14 | 2009-12-17 | マクロジェニクス,インコーポレーテッド | 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法 |
| CA2667613A1 (en) * | 2006-10-26 | 2008-06-05 | Wisconsin Alumni Research Foundation | Methods for reducing phosphate absorption |
| JP2010509235A (ja) * | 2006-11-03 | 2010-03-25 | ノースウェスタン ユニバーシティ | 多発性硬化症の治療 |
| CA2673470A1 (en) * | 2006-12-21 | 2008-07-03 | Macrogenics, Inc. | Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
| US20090131329A1 (en) * | 2007-09-14 | 2009-05-21 | Edmund John Miller | Treatment for allograft rejection |
| US20110200617A1 (en) * | 2008-01-18 | 2011-08-18 | Yaron Ilan | Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders |
| CA2718381A1 (en) * | 2008-03-13 | 2009-09-17 | Immuron Limited | Colostrum-derived immunoglobulin preparation comprising anti-insulin antibodies for the treatment of metabolic syndrome |
| CA2791975C (en) * | 2010-02-04 | 2021-02-09 | The Trustees Of The University Of Pennsylvania | Icos critically regulates the expansion and function of inflammatory human th17 cells |
| BR112012027531A2 (pt) * | 2010-04-29 | 2017-08-08 | Hadasit Medical Res Service And Development Co Ltd | método de tratamento e/ou prevenção de progresso e/ou atraso de desenvolvimento de hepatite em um indivíduo, uso de uma molécula imunológica anti-cd3 e composição farmacêutica |
| WO2012162067A2 (en) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| EP2714094B1 (en) | 2011-06-02 | 2016-02-24 | The University of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
| WO2013022091A1 (ja) * | 2011-08-11 | 2013-02-14 | 小野薬品工業株式会社 | Pd-1アゴニストからなる自己免疫疾患治療剤 |
| JP2015091761A (ja) * | 2012-02-23 | 2015-05-14 | 国立大学法人大阪大学 | 中枢神経の損傷を治療するための組成物およびその利用 |
| US20150132289A1 (en) * | 2012-02-29 | 2015-05-14 | Therapix Biosciences Ltd. | Methods and compositions for treating psc (primary sclerosing cholangitis) or pbc (primary biliary cirrhosis) with anti-cd3 immune molecule therapy |
| EP2892924B1 (en) | 2012-06-14 | 2020-11-25 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| KR101941004B1 (ko) * | 2013-03-25 | 2019-01-23 | 주식회사 엘지화학 | 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물 |
| HK1251488A1 (zh) | 2015-05-05 | 2019-02-01 | The University Of Louisville Research Foundation, Inc. | 作为放射致敏剂以及mri和/或x光造影剂的结合纳米粒子的抗核仁素剂 |
| EP3504241B1 (en) * | 2016-08-29 | 2024-05-15 | Tiziana Life Sciences PLC | Anti-cd3 antibody formulations |
| TWI849895B (zh) | 2018-02-09 | 2024-07-21 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| MX2020012598A (es) | 2018-05-24 | 2021-05-27 | Janssen Biotech Inc | Agentes aglutinantes del psma y usos de estos. |
| DE102018213030A1 (de) | 2018-08-03 | 2020-02-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien |
| AR118720A1 (es) | 2019-04-19 | 2021-10-27 | Janssen Biotech Inc | Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| US20230227555A1 (en) * | 2020-07-30 | 2023-07-20 | Tiziana Life Sciences Plc | Cd-3 antibodies for the treatment of coronavirus |
| MX2023008909A (es) | 2021-01-28 | 2023-10-23 | Janssen Biotech Inc | Proteínas de unión a psma y usos de estas. |
| US20220332822A1 (en) * | 2021-04-16 | 2022-10-20 | Tiziana Life Sciences Plc | Subcutaneous administration of antibodies for the treatment of disease |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| WO2023174925A1 (en) | 2022-03-14 | 2023-09-21 | Novimmune Sa | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4654210A (en) * | 1979-04-26 | 1987-03-31 | Ortho Pharmaceutical Corporation | Methods and compositions using complement fixing monoclonal antibody to human T cells |
| US4515893A (en) * | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4978745A (en) | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| CA1339256C (en) | 1989-01-26 | 1997-08-12 | Wulf Droge | Treatment of diseases associated with hiv-infections |
| DE69032484D1 (de) * | 1989-10-27 | 1998-08-20 | Arch Dev Corp | Zusammensetzungen und deren verwendung zur förderung der immunopotentiation |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| NZ243706A (en) | 1991-07-25 | 1994-08-26 | Idec Pharma Corp | Recombinant monkey antibodies, pharmaceutical compositions |
| US5756096A (en) * | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5556763A (en) * | 1992-04-06 | 1996-09-17 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Evaluation and treatment of patients with progressive immunosuppression |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| AU6983594A (en) * | 1993-06-28 | 1995-01-17 | Lion Corporation | Composition for oral cavity |
| US6090380A (en) * | 1994-01-12 | 2000-07-18 | Research Corporation Technologies, Inc. | Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin |
| US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| WO1998014209A1 (en) * | 1996-10-02 | 1998-04-09 | Ovimmune, Inc. | Oral administration of chicken yolk antibodies to treat disease |
| WO1998047531A2 (en) * | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
| US6007821A (en) | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
| US7041289B1 (en) * | 1997-12-05 | 2006-05-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for treating established spontaneous auto-immune diseases in mammals |
| EP1171161A1 (en) | 1999-04-19 | 2002-01-16 | Richard Weisbart | Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid |
| US6197328B1 (en) * | 1999-08-20 | 2001-03-06 | Dott Research Laboratory | Nasally administrable compositions |
| US6346247B1 (en) * | 1999-10-28 | 2002-02-12 | Promega Corporation | Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| AUPQ431299A0 (en) * | 1999-11-26 | 1999-12-23 | Unisearch Limited | Method of inducing immune tolerance |
| GB0001710D0 (en) * | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
| WO2001094419A2 (en) | 2000-06-07 | 2001-12-13 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Method to induce the th1 immune response |
| NZ526871A (en) * | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| AU2002327338A1 (en) | 2001-07-25 | 2003-02-17 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| GB2380127A (en) * | 2001-09-26 | 2003-04-02 | Isis Innovation | Treatment of chronic joint inflammation |
| US20030094173A1 (en) * | 2001-11-14 | 2003-05-22 | Inhale Therapeutic Systems, Inc. | Aerosolization device with improved endpiece connection |
| JP2005517025A (ja) | 2002-02-08 | 2005-06-09 | エクサイト セラピーズ, インコーポレイテッド | 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法 |
| CA2475388A1 (en) | 2002-02-14 | 2003-08-21 | William J. Rutter | Chimeric molecules for cleavage in a treated host |
| CA2479212A1 (en) * | 2002-03-15 | 2003-09-25 | Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
| US20040253237A1 (en) * | 2002-12-05 | 2004-12-16 | Ian Walters | Methods of treatment of ulcerative colitis with anti-CD3 antibodies |
| US20050042664A1 (en) * | 2003-08-22 | 2005-02-24 | Medimmune, Inc. | Humanization of antibodies |
| US7883703B2 (en) * | 2003-11-14 | 2011-02-08 | The Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| IL172175A0 (en) * | 2005-11-24 | 2011-08-01 | Hadasit Med Res Service | Beta glycolipids as immuno-modulators |
| US20110200617A1 (en) | 2008-01-18 | 2011-08-18 | Yaron Ilan | Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders |
-
2004
- 2004-11-12 US US10/987,380 patent/US7883703B2/en active Active
- 2004-11-12 CA CA2545806A patent/CA2545806C/en not_active Expired - Fee Related
- 2004-11-12 EP EP11162260.1A patent/EP2397189B1/en not_active Expired - Lifetime
- 2004-11-12 AU AU2004291107A patent/AU2004291107B2/en not_active Ceased
- 2004-11-12 WO PCT/US2004/037910 patent/WO2005048935A2/en not_active Ceased
- 2004-11-12 JP JP2006539927A patent/JP5027512B2/ja not_active Expired - Fee Related
- 2004-11-12 DK DK04810895.5T patent/DK1687066T3/da active
- 2004-11-12 EP EP04810895A patent/EP1687066B1/en not_active Expired - Lifetime
- 2004-11-12 ES ES04810895T patent/ES2393674T3/es not_active Expired - Lifetime
- 2004-11-12 PL PL04810895T patent/PL1687066T3/pl unknown
-
2010
- 2010-12-30 US US12/982,390 patent/US20110165177A1/en not_active Abandoned
-
2014
- 2014-11-07 US US14/535,693 patent/US9850305B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5828614B2 (ja) | ジアルキルフマレート含有薬剤調合物 | |
| AU2006345512A1 (en) | Controlled-release formulation | |
| KR20130036217A (ko) | 라퀴니모드를 이용한 루푸스 관절염의 치료 | |
| JP2020522560A5 (cg-RX-API-DMAC7.html) | ||
| CN105338970A (zh) | 包含他达拉非和坦洛新的药物胶囊复合制剂 | |
| CN108283643A (zh) | 一种噻嗪二酮类化合物在制备预防或治疗类风湿性关节炎的药物中的应用 | |
| CA3134145A1 (en) | Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine | |
| CN104546841A (zh) | 一种含有托匹司他的复方缓释制剂 | |
| CN101296696A (zh) | 一种用于治疗痛风的药物组合物及其制备方法和用途 | |
| CN1427728A (zh) | 胃排空能力测定用制剂 | |
| JP2013060427A (ja) | ロキソプロフェン及びペパーミント抽出物を含有する頻尿治療用組成物 | |
| JP6523328B2 (ja) | タンニン酸シタグリプチン複合体 | |
| CN119350175A (zh) | 一类新型酰基苯丙氨酸衍生物、其制备方法及其作为药物的用途 | |
| RU2015109933A (ru) | Композиции, включающие антитело и камостат мезилат (см) | |
| CN1414847A (zh) | 含吡喹酮的缓释抗蠕虫组合物 | |
| WO2004069246A1 (fr) | Compositions pour medicament renfermant des inhibiteurs de cholinesterase en vue du traitement de la demence senile | |
| CN102145004A (zh) | 己酮可可碱在制备预防或治疗功能性便秘的药物中的用途 | |
| TW201408293A (zh) | (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途 | |
| CN103040807A (zh) | 去-o-甲基毛狄泼老素在制备治疗高血压药物中的应用 | |
| CN102846571A (zh) | 一种埃索美拉唑镁微型片剂 | |
| CN100551369C (zh) | 一种含有西洛他唑的缓释制剂及其制备方法 | |
| CN1439371A (zh) | 苦参素缓释剂及其制备工艺 | |
| JP2026510895A (ja) | 経口バイオアベイラビリティを向上させるための医薬組成物 | |
| CN103285188B (zh) | 一种益气补肾活血的中药组合物及其制备方法 | |
| CN105902694A (zh) | 一种辅助冠心病术后恢复的药物组合物 |